1560 TRAPELO ROAD, WALTHAM, MA
Investor Presentation
Financial Results, Press Release
Announces Pricing of Upsized $375 Million Public Offering of Common Stock
Other Events
Barry E. Greene Elected as Class I Director at Dyne Therapeutics
Material disclosure
Dyne Therapeutics Elects Directors at 2026 Annual Meeting
Announces Completion of Enrollment in Registrational Expansion Cohort of ACHIEVE Trial of Z-Basivarsen for Myotonic Dystrophy Type 1 (DM1)
Q2
Q1
FY 2025
Q3
FY 2023
Prospectus filed pursuant to Rule 424(b)(5)
Registration Statement for Securities to be Offered to Employees
Definitive Proxy Statement
Additional Proxy Materials
PRE 14A
Statement of Changes in Beneficial Ownership
Notice of Proposed Sale of Securities